Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
about
Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumoniaDemographics, guidelines, and clinical experience in severe community-acquired pneumoniaCommunity acquired bacterial pneumoniaInterventions to improve antibiotic prescribing practices for hospital inpatientsProcalcitonin to initiate or discontinue antibiotics in acute respiratory tract infectionsProcalcitonin to initiate or withhold antibiotics in acute respiratory tract infectionsCombating antimicrobial resistance: policy recommendations to save livesSystematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infectionsProcalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unitAcute Phase Reactants in Infections: Evidence-Based Review and a Guide for CliniciansThe importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsisDuration of antimicrobial therapy in community acquired pneumonia: less is moreMeta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infectionsBiomarkers in community-acquired pneumonia: a state-of-the-art reviewTools for outcome prediction in patients with community acquired pneumonia.Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis.Procalcitonin for clinical decisions on influenza-like illness in emergency department during influenza a(H1N1)2009 pandemic.Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia.Revolutionizing clinical microbiology laboratory organization in hospitals with in situ point-of-careDiagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial.Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia.Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency departmentProcalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort studyDiagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stayWhich patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relativesSerial Procalcitonin as a Predictor of Bacteremia and Need for Intensive Care Unit Care in Adults With Pneumonia, Including Those With Highest Severity: A Prospective Cohort StudyUsing Procalcitonin to Guide Antibiotic Therapy.Association of adrenal function and disease severity in community-acquired pneumonia.Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome.Predicting treatment failure in severe sepsis and septic shock: looking for the Holy GrailNeonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention StClinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumoniaCorticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trialDefining and predicting severe community-acquired pneumonia.Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients.Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trialEarly alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection.Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.
P2860
Q21194921-B00ED32E-D6F1-43AC-BD7A-74CE235251C3Q21195015-C7DB85DD-D4EE-4C2C-9446-73C546609CBBQ22241379-5F0D7267-0F33-4890-A8DC-11E0E9D33E28Q24197807-9D959460-E0A9-438D-AB7C-F460F68594D2Q24200676-8B04317D-F7DB-4607-8D17-125E1C0B5715Q24241768-35C8DEBA-517C-46D9-B869-CC19DC827602Q24632857-A4245ADB-2DAB-4FC2-BE02-08A9E1E51619Q26782662-BD7935DE-EC31-4855-8950-DDFEFBABB265Q26798459-D576716D-006D-4DC9-8607-2D6DEBD626F6Q26799899-330409AB-89C6-4F96-94C9-4AA5C45F8B65Q26827765-AA19AA8E-0BD8-4F88-9D01-58ACF84BEEE4Q26828493-85A75FD4-8ADF-4E3C-ADB4-982A6D600062Q27023057-51A1FE64-7EF5-49AB-B1A1-C7990F0A31BFQ27026995-9118C050-5C63-4C92-8EDC-2AE9CA69E314Q30240254-C9D97251-5B15-43C5-BD78-8CA5C691DF43Q30360003-7F5D282D-14D7-4062-83F9-1D20ABC9EAF6Q30396773-6ADA471E-ACA1-473C-BD35-5C1FFDA5E9D5Q30403782-1E19DCA1-A925-4F44-937D-03DFBF13F0A3Q31029164-4E96D194-6E03-47BE-9813-7112F5201DFAQ33276665-D917FCC2-28C8-4EC8-B17B-7EA010F77277Q33290142-C177068A-EA4A-4510-9253-CED7AA2FEEA7Q33321452-0619F6C9-881E-4403-809C-EDDBFC6B910AQ33400876-D724FD53-F408-487E-9C53-E69DAD6954FAQ33505806-0923125B-3316-4009-9F9D-36180BC8CEE3Q33520362-1B418DDC-40E7-4142-938F-4B2D1EFEBB64Q33540012-53928E2D-72FE-479F-928C-83CFBDE93D29Q33629533-E5F4D5C2-F136-4F83-B820-AB946CD303A5Q33629591-A1E226B9-602B-44E6-9FB0-2423499817CBQ33728018-CE75B4B3-D5C1-4844-8D7B-0584794707E5Q33749972-F990707C-F26C-4648-A19F-12E490B9A559Q33753353-B067CA7C-0010-4169-B020-45CA1E5E633CQ33766905-DB32FCF6-0EE5-4F5C-9D3D-486326CE14B3Q33827245-6D7FE419-9C80-4520-A40D-9A9D8D4A847BQ33853198-B1737CBD-D753-47F1-A10D-26B09DE0AEECQ33872274-B46ED076-2925-4F92-A330-C9CFAD5F5FF7Q33889170-0C38492C-34A8-4129-A7A2-28367E05E094Q34001903-E1639AFA-C5EE-44AA-B185-CF62F1CBD03AQ34017829-9442F36A-958E-448D-B7AE-099E516AAC33Q34026905-F70D1156-B6AC-4469-9638-B72F8B372A41Q34026963-BAC4AEFF-5EA1-4E61-AC85-BD898B0C23B4
P2860
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
description
im Juli 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2006
@uk
name
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
@en
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
@nl
type
label
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
@en
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
@nl
prefLabel
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
@en
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
@nl
P2093
P2860
P50
P1476
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
@en
P2093
Beat Müller
Christian Müller
Daiana Stolz
David Miedinger
Michael Tamm
Peter R. Huber
Werner Zimmerli
P2860
P356
10.1164/RCCM.200512-1922OC
P407
P577
2006-07-01T00:00:00Z